TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

This trial studies a new radiation approach for esophageal squamous cell cancer (cancer of the swallowing tube) that intentionally spares lymph nodes near the tumor site. These lymph nodes are thought to help the immune system and immunotherapy work better. The study combines this targeted radiation with chemotherapy and immunotherapy. **You may be eligible if...** - You are 18–75 years old - You have confirmed squamous cell cancer of the esophagus - Your cancer is locally advanced (has not spread widely) - Your general performance level is good enough for treatment **You may NOT be eligible if...** - Your cancer has spread to distant organs beyond certain lymph nodes - You have had prior radiation to the chest or esophagus - You have autoimmune disease or conditions that prevent immunotherapy use - You have severe heart, lung, or liver problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.